Primary Hyperoxaluria Clinical Trials in New York, New York
2 recruitingNew York, New York
Showing 1–2 of 2 trials
Recruiting
Phase 2
Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD
End Stage Renal DiseasePrimary Hyperoxaluria Type 1
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company28 enrolled18 locationsNCT04580420
Recruiting
Rare Kidney Stone Consortium Patient Registry
CystinuriaDent DiseasePrimary Hyperoxaluria+1 more
Mayo Clinic730 enrolled4 locationsNCT00588562